Emergent Biosolutions Inc. (NYSE:EBS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Emergent Biosolutions Inc. (NYSE:EBS) have earned an average recommendation of “Hold” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $12.00.

Several equities analysts have recently issued reports on the stock. Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Weiss Ratings cut shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Finally, UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd.

Emergent Biosolutions Stock Performance

EBS opened at $7.28 on Wednesday. The business’s 50 day moving average is $8.16 and its 200-day moving average is $9.13. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10. The stock has a market cap of $375.80 million, a PE ratio of -26.01 and a beta of 2.34. Emergent Biosolutions has a twelve month low of $5.61 and a twelve month high of $14.06.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.46. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.The company had revenue of $156.10 million during the quarter, compared to analysts’ expectations of $145.00 million.

Insider Activity

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 17,202 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $144,496.80. Following the sale, the director directly owned 79,941 shares of the company’s stock, valued at $671,504.40. The trade was a 17.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paul Anthony Williams sold 3,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president directly owned 159,098 shares of the company’s stock, valued at approximately $1,336,423.20. This trade represents a 1.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 64,925 shares of company stock worth $543,512. 6.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Emergent Biosolutions

Several institutional investors and hedge funds have recently bought and sold shares of EBS. Legal & General Group Plc purchased a new stake in shares of Emergent Biosolutions in the second quarter worth approximately $31,000. Torren Management LLC purchased a new position in Emergent Biosolutions during the fourth quarter valued at approximately $37,000. CANADA LIFE ASSURANCE Co acquired a new position in Emergent Biosolutions in the 4th quarter valued at approximately $45,000. Raymond James Financial Inc. acquired a new position in Emergent Biosolutions in the 2nd quarter valued at approximately $53,000. Finally, Farther Finance Advisors LLC increased its stake in Emergent Biosolutions by 361.3% in the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 4,827 shares during the period. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.